BioNTech (BNTX) Set to Announce Earnings on Monday

BioNTech (NASDAQ:BNTX) will be releasing its earnings data before the market opens on Monday, May 6th. Analysts expect BioNTech to post earnings of ($0.45) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

BioNTech (NASDAQ:BNTX) last released its earnings results on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing the consensus estimate of $2.64 by ($0.59). The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $2.04 billion. BioNTech had a net margin of 24.26% and a return on equity of 4.60%. On average, analysts expect BioNTech to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

BioNTech Trading Up 0.5 %

Shares of NASDAQ:BNTX opened at $92.72 on Friday. BioNTech has a twelve month low of $85.21 and a twelve month high of $125.83. The company has a current ratio of 9.43, a quick ratio of 9.26 and a debt-to-equity ratio of 0.01. The firm has a market cap of $22.04 billion, a P/E ratio of 22.39 and a beta of 0.25. The company has a 50 day moving average of $90.56 and a 200-day moving average of $96.01.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on BNTX. Oppenheimer began coverage on BioNTech in a research report on Friday, January 5th. They set a “market perform” rating on the stock. HC Wainwright restated a “buy” rating and set a $107.00 price objective on shares of BioNTech in a research report on Wednesday, April 17th. JPMorgan Chase & Co. dropped their target price on shares of BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a report on Friday, March 22nd. BMO Capital Markets reduced their target price on shares of BioNTech from $127.00 to $123.00 and set an “outperform” rating for the company in a report on Thursday, March 21st. Finally, UBS Group cut their price objective on BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a research report on Wednesday, March 27th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, BioNTech has a consensus rating of “Hold” and a consensus target price of $120.40.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.